FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor
Source: kpvi.com
Median Duration News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Median Duration. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Median Duration Today - Breaking & Trending Today
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the...
Source: prnewswire.com
EU regulator backs AstraZeneca and Daiichi's lung cancer drug
The recommendation is based on the mid-stage data that showed Enhertu reduced the tumour by 49% and the median duration of response by 16.8 months in patients previously treated for lung cancer. The drug is already approved in the European Union as a treatment for patients with an advanced form of breast cancer.
Source: yahoo.com
Iovance Biotherapeutics Announces 33-Month Follow Up Data
Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study Early Intervention with Lifileucel...
Source: globenewswire.com
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma During American Association for Cancer Research (AACR) 2021 Annual Meeting
Published: Apr 09, 2021 Median Duration of Response Not Reached at 28.1 Months of Median Study Follow Up in Cohort 2 of C-144-01 Study 36.4% Overall Response Rate; Continued Deepening of Responses SAN CARLOS, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma. These data will be part of an oral presentation in a Clinical Trials Plenary Session at the upcoming American Asso...
Source: biospace.com